Phenix

HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 6, 2022

Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

FIXX ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed

Retrieved on: 
Monday, April 4, 2022

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

FIXX ALERT: Investors with Substantial Losses Have Opportunity to Lead Homology Medicines, Inc. Class Action Lawsuit

Retrieved on: 
Saturday, April 2, 2022

If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here .

Key Points: 
  • If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here .
  • Lead plaintiff motions for the Homology Medicines class action lawsuit must be filed with the court no later than May 24, 2022.
  • THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Homology Medicines securities during the Class Period to seek appointment as lead plaintiff in the Homology Medicines class action lawsuit.
  • A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.

HOMOLOGY MEDICINES, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Homology Medicines, I

Retrieved on: 
Thursday, March 31, 2022

You may obtain additional information concerning the action or join the case on our website, www.whafh.com.

Key Points: 
  • You may obtain additional information concerning the action or join the case on our website, www.whafh.com.
  • If you have incurred losses in Homology Medicines, Inc. you may, no later than May 24, 2022, request that the Court appoint you lead plaintiff of the proposed class.
  • Please contact Wolf Haldenstein to learn more about your rights as an investor in Homology Medicines, Inc..
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Thursday, March 31, 2022

On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.

Key Points: 
  • On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • If you purchased FIXX securities, and/or would like to discuss your legal rights and options please visit Homology Medicines, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Thursday, March 31, 2022

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed

Retrieved on: 
Monday, March 28, 2022

SAN FRANCISCO, March 28, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 28, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. (FIXX)

Retrieved on: 
Monday, March 28, 2022

Investors who purchased or otherwise acquired shares of Homology should contact the Firm prior to the May 24, 2022 lead plaintiff motion deadline.

Key Points: 
  • Investors who purchased or otherwise acquired shares of Homology should contact the Firm prior to the May 24, 2022 lead plaintiff motion deadline.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Retrieved on: 
Wednesday, March 23, 2022

BEDFORD, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2021, and highlighted recent accomplishments.

Key Points: 
  • The Company has already incorporated this regimen into its pheEDIT gene editing trial for adults with PKU.
  • As a result, the Company now expects to provide a program update when the path forward is established with FDA.
  • As of December 31, 2021, Homology had approximately $155.9 million in cash, cash equivalents and short-term investments.
  • Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease.

FIXX Shareholder Class Action: Robbins LLP Reminds Investors of Class Action Against Homology Medicines, Inc. (FIXX)

Retrieved on: 
Wednesday, March 30, 2022

The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Homology Sciences, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Homology Sciences, Inc. (NASDAQ: FIXX) securities between June 10, 2019 and February 18, 2022, for violations of the Securities Exchange Act of 1934.
  • Homology is a genetic medicines company that focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The Company's lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults.
  • If you would like more information about Homology Medicines, Inc.'s misconduct, click here .